Kura Oncology
KURA
116 hedge funds and large institutions have $610M invested in Kura Oncology in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 53 increasing their positions, 31 reducing their positions, and 16 closing their positions.
122% more call options, than puts
Call options by funds: $40K | Put options by funds: $18K
71% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 31
1.25% more ownership
Funds ownership: 87.74% → 88.99% (+1.3%)
5% less funds holding
Funds holding: 122 → 116 (-6)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
20% less capital invested
Capital invested by funds: $762M → $610M (-$151M)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$33.1M |
| 2 |
BlackRock
New York
|
+$10.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.47M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$5.33M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$5.1M |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$22M |
| 2 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$8.01M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
-$7.34M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$5.51M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.1M |
KURA Hedge Fund Activity: Q3 2019 in Review
116 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q3 2019, worth a combined $610M — down 20% from $762M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of KURA and 10 opened new positions — a net loss of 6 holders — while 31 trimmed existing stakes and 53 added.
The largest buyer was Fidelity Investments, adding an estimated $33.1M. The largest seller was EcoR1 Capital, cutting an estimated $22M.
- 116 institutional investors held Kura Oncology (KURA) as of Q3 2019, down from 122 in Q2 2019.
- Funds reported $610M of Kura Oncology stock for Q3 2019, down 20% quarter-over-quarter.
- 10 funds opened new Kura Oncology positions in Q3 2019 and 16 closed out, a net change of -6 holders.
- The largest Kura Oncology buyer in Q3 2019 was Fidelity Investments, an estimated $33.1M added.
- The largest Kura Oncology seller in Q3 2019 was EcoR1 Capital, an estimated $22M sold.
Based on aggregated 13F filings for Q3 2019.